Renal Impairment clinical trials

Explore recruiting renal impairment clinical trials.

Recruiting renal impairment studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Renal Impairment trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1, Open-Label, Non-Randomized, Single-Center, Single-Dose Study to Assess the Pharmacokinetics and Safety of ANT3310 Combined with Meropenem Administered as a Single Intravenous Infusion to Adult Subjects with Renal Function Impairment

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

A study to test how kidney problems influence the blood concentrations of efgartigimod

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

An Open-label, Single-dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-77242113 in Adult Participants

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

Effect of Renal Impairment on Enpatoran Pharmacokinetics

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 and Severe Renal Impairment, With or Without Dialysis

Germany, Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1 Open-label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Obeldesivir in Participants With Normal Renal Function and Renal Impairment

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

Renal Impairment trials by city

Renal Impairment in Toronto Renal Impairment in Vancouver Renal Impairment in Montreal Renal Impairment in Calgary Renal Impairment in Edmonton Renal Impairment in Ottawa Renal Impairment in Winnipeg Renal Impairment in Quebec City Renal Impairment in Hamilton Renal Impairment in Kitchener Renal Impairment in London Renal Impairment in Halifax Renal Impairment in New York Renal Impairment in Los Angeles Renal Impairment in Chicago Renal Impairment in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease